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ABSTRACT 
Lafora progressive myoclonus epilepsy (LD) is a fatal autosomal recessive 
neurodegenerative disorder characterized by the presence of glycogen-like intracellular 
inclusions called Lafora bodies. LD is caused by mutations in two genes, EPM2A and 
EPM2B, encoding respectively laforin, a dual-specificity protein phosphatase, and 
malin, an E3 ubiquitin ligase. Previously, we and others have suggested that the 
interactions between laforin and PTG (a regulatory subunit of type 1 protein 
phosphatase) and between laforin and malin are critical in the pathogenesis of LD. Here, 
we show that the laforin-malin complex downregulates PTG-induced glycogen 
synthesis in FTO2B hepatoma cells through a mechanism involving ubiquitination and 
degradation of PTG. Furthermore, we demonstrate that the interaction between laforin 
and malin is a regulated process that is modulated by the AMP-activated protein kinase 
(AMPK). These findings provide further insights into the critical role of the laforin-
malin complex in the control of glycogen metabolism and unravel a novel link between 
the energy sensor AMPK and glycogen metabolism. These data advance our 
understanding of the functional role of laforin and malin, which hopefully will facilitate 
the development of appropriate LD therapies. 
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INTRODUCTION 
Lafora progressive myoclonus epilepsy (LD, OMIM 254780) is an autosomal 
recessive neurodegenerative disorder characterized by the presence of glycogen-like 
intracellular inclusions named Lafora bodies [(1), (2), (3), (4), (5)]. LD is a fatal 
disorder that occurs worldwide, but is relatively more frequent in Mediterranean 
countries. LD initially manifests during adolescence with generalized tonic-clonic 
seizures, myoclonus, absences, drop attacks or visual hallucinations. As the disease 
proceeds, a rapidly progressive dementia with apraxia, aphasia and visual loss ensues, 
leading patients to a vegetative state and death, usually within the first decade from 
onset of the first symptoms [(6), (7)]. Mutations have been identified in two genes, 
EPM2A [(8), (9)] and EPM2B (10), although there is evidence for a third locus (11). 
EPM2A, located on chromosome 6q24 [(12), (13)], is mutated in approximately 60% of 
LD cases. EPM2A encodes laforin, a dual-specificity protein phosphatase of 331 amino 
acids with a functional carbohydrate binding domain at the N-terminus [(14), (15)]. 
Several proteins have been recently reported to interact with laforin (7): i) a protein of 
unknown function named EPM2AIP1 (16); ii) HIRIP5, a cytosolic protein with a 
housekeeping function that may be involved in iron homeostasis (17); iii) GSK3, a 
crucial component of both, the Akt/PKB kinase and the Wnt signaling pathways [(18), 
(19)]; and iv) R5/PTG (20), one of the glycogen-targeting regulatory subunits of type 1 
protein phosphatase (PP1) which favors the assembly of PP1 with its substrates, 
glycogen synthase (GS), phosphorylase (Ph) and phosphorylase kinase (PhK), and 
enhances glycogen accumulation [(21), (22), (23)]. Laforin thus appears to be part of a 
multiprotein complex that may be associated with the formation of intracellular 
glycogen particles. In fact, using multiple mouse models, it has been recently described 
that the levels of laforin protein closely correlate with the levels of intracellular 
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glycogen. This observation suggests a direct relationship between laforin and glycogen 
levels (24). In addition, it has been described that laforin is able to form homodimers 
[(20), (25)], which is critical for the phosphatase activity of laforin. Laforin has also 
been implicated in the Wnt signaling pathway, as it has been reported to 
dephosphorylate GSK3(25). However, multiple reports have since demonstrated 
by several methods that GSK3 is not a substrate of laforin [(26), (27)]. Thus, the 
physiological relevance of the interaction between laforin and GSK3 is controversial. 
A second gene, EPM2B, located on chromosome 6p22.3, was recently found to 
be mutated in 20-30% of LD patients [(10), (28)]. EPM2B encodes malin, an E3 
ubiquitin ligase of 395 aa with a RING finger domain at the N-terminus and six NHL 
domains in the C-terminal region [(10), (18), (29)]. It has been recently described that 
malin interacts with and ubiquitinates laforin, leading to its degradation (29). 
Both the formation of laforin-malin complexes and the observation that patients 
with mutations in laforin or malin are neurologically and histologically 
indistinguishable [(28), (30)], strongly suggest that the two LD proteins operate through 
common physiological pathways. 
In this report, we show that the laforin-malin complex downregulates PTG-
induced glycogen synthesis in FTO2B hepatoma cells through a mechanism involving 
ubiquitination and degradation of PTG, similar to that recently described in neuronal 
cells (31). Most importantly, we show that the formation of the laforin-malin complex is 
a regulated process and that AMP-activated protein kinase (AMPK) plays a critical role 
in this regulation. The involvement of AMPK in the regulation of the laforin-malin 
complex adds a metabolic component to our understanding of the pathogenesis of LD. 
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RESULTS 
Impaired formation of laforin-malin-PTG complexes is critical in the pathogenesis of 
LD. 
Yeast two-hybrid analysis and pull-down assays demonstrated that laforin 
interacted physically with malin, in agreement with recent reports [(18, 29)]. Moreover, 
the laforin binding site was located within the four C-terminal NHL domains of malin 
(residues 208-395) (data not shown). Similarly, functional analysis of several laforin 
and malin mutations identified in patients with LD indicated that the formation of the 
laforin-malin complex and its interaction with PTG is crucial in LD pathogenesis 
(Supplementary material Fig. S1). Since laforin forms stable complexes with malin and 
also interacts with PTG, we tested whether malin also interacted with PTG. Although, 
we could not detect a direct interaction between malin and PTG, a robust two-hybrid 
interaction between PTG and malin was observed when laforin was overexpressed in 
these assays (Fig. 1). These results suggest the formation of a possible ternary complex 
in which laforin would tether the interaction between malin and PTG. Similar results 
were obtained with laforin C266S, an artificial laforin mutant that interacts properly 
with malin, but lacks phosphatase activity (Supplementary material Fig. S1), indicating 
that the formation of ternary complexes between laforin, malin and PTG did not require 
the phosphatase activity of laforin (Fig. 1). 
 
The laforin-malin complex prevents glycogen accumulation caused by overexpression 
of PTG in FTO2B hepatoma cells, ubiquitinates PTG and targets it for degradation 
Recently, we described a novel mechanism for the regulation of glycogen 
synthesis that involves the laforin-malin complex in neurons. This regulatory 
mechanism controls the levels of glycogen synthase and PTG via a proteasomal 
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degradation pathway (31). Because disturbance of this novel glycogen regulatory 
mechanism, as a consequence of mutations in laforin or malin, may explain the 
generation of the glycogen-like intracellular inclusions (Lafora bodies) present in all 
tissues of LD patients, we determined whether this glycogen regulatory mechanism also 
operates in tissues that normally synthesize glycogen, such as liver. Using FTO2B 
hepatoma cells as a model system, we observed that treatment of these cells with 
increasing amounts of adenovirus expressing a GFP-PTG fusion protein (Ad-GFP-PTG) 
resulted in a dose-dependent enhancement of glycogen accumulation (Fig. 2A). The 
PTG-induced glycogen accumulation was, however, progressively prevented by the co-
infection of FTO2B cells with increasing amounts of adenovirus expressing laforin (Ad-
laforin) and malin (Ad-malin) (Fig. 2B). This effect was dependent on the presence of 
both laforin and malin, since in the absence of one of them, no inhibition of the 
glycogenic properties of PTG was observed (Fig. 2B). The co-expression of laforin and 
malin with GFP-PTG in FTO2B cells resulted in a drastic reduction in the levels of 
GFP-PTG (Fig. 2C). The levels of laforin were also diminished, in agreement with a 
recent report indicating that malin interacts with and ubiquitinates laforin, leading to its 
degradation (29). However, the co-expression of laforin and malin did not change the 
total levels of glycogen synthase in FTO2B cells. This result is consistent with the 
observation that only the muscular glycogen synthase isoform (MGS), but not the liver 
isoform (LGS), is degraded by the overexpression of laforin and malin in neuron cells 
((31) and unpublished results), suggesting the existence of tissue-specific differences in 
the regulation of glycogen synthesis by the laforin-malin complex. We also found that 
the levels of accumulated glycogen correlated directly with the activity of GS. We 
observed an increase in the GS activity ratio (-Glu-6P/+Glu-6P) when the cells were 
infected with Ad-GFP-PTG adenovirus (ratio of 0.46 v.s. 0.13, observed in cells 
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infected with Ad-GFP adenovirus) and a decrease in the GS activity ratio when the cells 
were co-infected with Ad-GFP-PTG, Ad-laforin and Ad-malin (ratio of 0.34). 
Consistent with these results, we observed a partial recovery of the phosphorylated 
status of GS at Ser461 when the cells were co-infected with Ad-GFP-PTG, Ad-laforin 
and Ad-malin adenovirus (a sign of GS inactivation). These results indicated an 
inhibition of the dephosphorylating activity of PTG under the later conditions, possibly 
as a consequence of lower levels of this protein (Fig. 2C). 
To determine whether the reduction in the levels of PTG was due to an increased 
ubiquitin-dependent proteasomal degradation, mediated by the laforin-malin complex, 
we expressed in HEK293 cells a myc-tagged form of PTG (myc-PTG) and a modified 
form of ubiquitin (tagged with 6xHis residues), which allowed the purification of 
ubiquitin-tagged proteins by metal affinity chromatography (TALON column; see 
Materials and Methods). As observed in Fig. 3, in the bound fraction of the TALON 
column, the anti-myc antibody detected a poly-dispersed high molecular weight 
material (lanes 2 and 3), which was absent in the cells that expressed myc-PTG, but not 
the modified form of ubiquitin (lane 1), indicating that myc-PTG was ubiquitinated in 
vivo (Ub-myc-PTG). Interestingly, the co-expression of laforin and malin improved the 
ubiquitination of myc-PTG (lane 3) in comparison with cells that only co-expressed 
malin (lane 2) or with cells that did not co-express laforin and malin (not shown). No 
high molecular weight forms of myc-PTG were observed in the crude extracts, possibly 
due to the low abundance of these forms due to their rapid degradation. These results 
suggest that the laforin-malin complex modified PTG and targeted it for ubiquitin-
dependent proteasomal degradation. The affinity column also retained unspecifically the 
unmodified form of myc-PTG, perhaps due to the polysaccharide binding domain 
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present in PTG that reacted with the polysaccharide base of the TALON column (Fig. 3, 
asterisk). 
 
The laforin-malin interaction is modulated by the AMP-activated protein kinase. 
Since laforin and malin formed a functional complex (see above), we studied 
next how the formation of this complex could be regulated. Two-hybrid analysis of 
yeast cells co-transformed with laforin and malin demonstrated a three-fold increase of 
the laforin-malin interaction when the cells were incubated in low (0.05%) glucose 
containing medium (Fig. 4A). These conditions in yeast determine activation of the 
Snf1 kinase, the orthologue of the human catalytic subunit of the AMP-activated protein 
kinase (AMPK), a metabolic-sensing protein that plays a key role in maintaining the 
cellular energy balance (32). AMPK is a serine/threonine protein kinase that acts as a 
sensor of the cellular energy status. Once activated, it switches on catabolic pathways 
and switches off many ATP-consuming processes including anabolic pathways [see 
(33), (34), (35), (36), for review]. Activation of AMPK requires phosphorylation of the 
 catalytic subunit by an upstream kinase, with LKB1 and CaMKK sharing this role 
[(37), (38), (39), (40)]. 
To test whether the Snf1 kinase modulated the interaction between laforin and 
malin, we used a yeast mutant lacking the Snf1 kinase (snf1) and observed that the 
interaction between laforin and malin did not increase in the presence of low (0.05%) 
glucose conditions (Fig. 4B). Concurrently, transformation of wild type yeast cells with 
a constitutively activated form of the catalytic subunit of mammalian AMPK [KD 
T172D; (41), (42)] increased the interaction between laforin and malin in high (4%) 
glucose conditions, to levels comparable to those observed in low (0.05%) glucose (Fig. 
4C). 
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In contrast to other eukaryotes, yeast accumulates glycogen when growing under 
low glucose conditions. To demonstrate that the increase in the interaction between 
laforin and malin was due to the action of Snf1/AMPK proteins and not to the 
accumulation of glycogen, we measured the interaction in a gac1 yeast mutant, lacking 
the main regulatory subunit of the type 1 protein phosphatase (yeast PTG orthologue), 
that targets the phosphatase catalytic subunit to substrates involved in glycogen 
metabolism. This mutant is unable to accumulate glycogen, whereas the Snf1 pathway 
is still activated upon growth in low glucose conditions (43). As shown in Fig. 4B, the 
interaction between laforin and malin increased in the gac1 mutant when growing in 
low (0.05%) glucose conditions, as observed in the wild type control. In addition, we 
did not observe any accumulation of glycogen in cells growing in high (4%) glucose 
and expressing the plasmid pSK-KDT172D (data not shown). These data suggested that 
the increase in the interaction between laforin and malin was related to the action of 
Snf1/AMPK proteins and not to the accumulation of glycogen in yeast cells. This 
modulation seems specific for the interaction between laforin and malin since AMPK 
activation did not affect the interaction between laforin and PTG (data not shown). 
 
AMPK interacts and phosphorylates laforin in vitro. 
AMPK is a heterotrimer comprised of a catalytic subunit (), a scaffolding 
subunit () also involved in substrate recognition, and a regulatory subunit (). To 
characterize the potential interaction between laforin and/or malin and AMPK, we 
performed a yeast two hybrid analysis with the 2, 2 and 1 AMPK subunits, the most 
abundant isoforms found in liver and skeletal muscle. These analyses showed that 
laforin interacted with the catalytic AMPK2 and the AMPK2 scaffolding subunits, 
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but not with AMPK1 (Fig. 5A). These interactions were not regulated by the level of 
glucose (data not shown). In contrast to laforin, malin did not interact with any of the 
AMPK subunits (Fig. 5A) (an empty LexA plasmid in combination with the three 
AMPK subunits gave less than 1 Unit of -galactosidase activity; not shown). We 
confirmed that laforin interacted with AMPK in vivo by co-immunoprecipitation 
experiments using HEK293 cells transfected with pCINeo::Laforin and pCMV-HA-
AMPK2. As shown in Fig. 5B, cell extracts immunoprecipitated using an anti-HA 
monoclonal antibody (to immunoprecipitate AMPK2) co-immunoprecipitated laforin. 
We next analyzed whether purified AMPK could phosphorylate GST::laforin in vitro. 
These in vitro experiments, in addition to further corroborating the interaction between 
laforin and AMPK, demonstrated that AMPK was able to phosphorylate recombinant 
GST::laforin produced in bacteria (Fig. 5C). Taken together, these data suggest that 
AMPK might be involved in the regulation of the laforin-malin complex. 
 
A dominant negative form of AMPK impairs the effect of the laforin-malin complex 
on the glycogenic activity of PTG. 
Following our observations that the laforin-malin complex downregulates the 
glycogenic activity of PTG and that the interaction between laforin and malin is 
regulated by AMPK, we postulated that the disruption of the endogenous laforin-malin 
complex by expressing a dominant negative form of the catalytic subunit of AMPK (1-
D157A; DN-AMPK) should result in an enhancement in the glycogenic activity of 
PTG. In agreement with this idea, co-infection of FTO2B cells with Ad-GFP-PTG and 
Ad-DN-AMPK adenovirus resulted in a statistically significant enhancement of the 
glycogenic activity of PTG (Fig. 6A). Co-infection of Ad-DN-AMPK with an 
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adenovirus expressing only GFP (Ad-GFP) did not increase glycogen accumulation, 
indicating that DN-AMPK by itself did not have glycogenic activity. We also analyzed 
the effect of AMPK activation. Treatment of Ad-GFP-PTG infected cells with AICAR 
(0.5 mM, 6 hours, to activate endogenous AMPK) did not change the amount of 
accumulated glycogen in comparison with untreated Ad-GFP-PTG infected cells (Fig. 
6A). 
We tested next whether DN-AMPK could prevent the downregulation of the 
glycogenic activity of PTG induced by the overexpression of laforin-malin complex. 
FTO2B cells co-infected with Ad-GFP-PTG, Ad-DN-AMPK, Ad-laforin and Ad-malin 
adenovirus showed a statistically significant increase in the glycogenic activity of PTG 
(Fig. 6B), as compared to the cells that were not infected with Ad-DN-AMPK, 
suggesting that the DN-AMPK prevented the downregulatory action of the laforin-
malin complex, likely by interfering with the laforin-malin interaction. In this sense, 
western blot analysis indicated a partial recovery of the levels of GFP-PTG in the cells 
co-infected with the four adenovirus (Fig. 6C). Interestingly, the levels of laforin were 
also higher in this case (Fig. 6C), perhaps as a consequence of the impairment of the 
interaction between laforin and malin. 
We suggested above that the increase in the glycogenic properties of PTG 
produced by the co-infection with Ad-DN-AMPK (Fig. 6A) was due to the disruption of 
the endogenous laforin-malin complex. If our hypothesis was correct, elimination of 
laforin or malin from the cells should prevent the DN-AMPK-mediated enhancement of 
the glycogenic activity of PTG. To address this point, we used two primary fibroblasts 
cell lines derived from LD patients carrying the laforin mutations Y86X and R241X, 
respectively, and cell lines from healthy control fibroblasts. These fibroblasts were 
infected with Ad-GFP-PTG and/or Ad-DN-AMPK adenovirus. Fig. 7A illustrates an 
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enhanced accumulation of glycogen in all fibroblast cell lines when they were infected 
with Ad-GFP-PTG, which was higher in LD-derived fibroblasts. However, in contrast 
to healthy control fibroblasts, the co-infection with Ad-DN-AMPK of LD-derived 
fibroblasts did not enhance the glycogenic activity of PTG. These results suggest that in 
the absence of functional laforin-malin complex (either because one of the components 
is missing or because the formation of the functional complex is prevented), the 
glycogenic activity of PTG is at maximum. 
 
DISCUSSION 
Lafora progressive myoclonus epilepsy (LD) is caused by mutations in the 
EPM2A or EPM2B genes, encoding laforin or malin, respectively. Although the roles of 
these two proteins in cellular physiology are still poorly understood, several reports 
have provide evidence suggesting that the disruption of protein-protein interactions 
involving laforin and malin are critical for the pathogenesis of LD. One of the 
histological determinants characteristic of LD is the accumulation of glycogen-like 
intracellular inclusions named Lafora bodies. Glycogen metabolism is mainly regulated 
by the phosphorylation of the proteins involved in glycogen synthesis (glycogen 
synthase, GS) and degradation (glycogen phosphorylase, Ph and glycogen 
phosphorylase kinase, PhK) [(44), (45)]. Interestingly, while there are several kinases 
(AMPK, PKA, CKI, GSK3, etc) that inhibit glycogen synthesis by the phosphorylation 
of GS, there is only one known phosphatase (PP1) that induces glycogen synthesis by 
activating GS and inactivating the glycogen degradation enzymes Ph and PhK [(44), 
(45)]. PP1 is recruited to glycogen by a family of glycogen targeting proteins including 
GM, GL, PTG and R6 [(44), (45), (46)], whose overexpression results in glycogen 
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accumulation [(21), (46)]. In this study, we present evidence for the critical role of the 
interaction between laforin, malin and PTG in LD pathogenesis. 
We show here that laforin and malin play a crucial role in the regulation of 
glycogen biosynthesis in FTO2B hepatoma cells. In these cells, the laforin-malin 
complex counteracts the glycogenic effect of PTG because it promotes its ubiquitination 
and degradation. It has been described that in this type of cells PTG preferentially 
affects Ph and PhK over GS [(47), (48), (49)]. Therefore, the laforin-malin dependent 
inactivation of PTG may ensure that Ph and PhK remain phosphorylated (active), which 
would prevent glycogen accumulation (Fig. 8). This mechanism is analogous to the one 
recently described in neurons (31). However, in neuronal cells, where no Ph and PhK 
are present but GS is clearly expressed [(31), (50)], the role of the laforin-malin 
complex may be critical to maintain glycogen synthesis silenced in a cell that does not 
have the ability to degrade glycogen. LD patients lacking a functional laforin-malin 
complex would be unable to regulate PTG and GS, leading to glycogen accumulation in 
neurons (Fig. 8). Consistent with this interpretation, an LD patient with mutations in 
laforin shows a dramatic increase in the total levels of GS in skeletal muscle compared 
to a control individual (SRdeC, unpublished results). Further studies would be needed to 
reconcile these data with early studies in LD patients (51) and studies in mouse models 
[(26), (52)] reporting that the activity of the enzymes involved in glycogen metabolism 
is not markedly affected. 
Since the role of the laforin-malin complex is critical, we hypothesized that the 
formation of the laforin-malin complex must be also tightly regulated. Here, we provide 
evidence indicating that the formation of the laforin-malin complex is positively 
regulated by AMPK. We show that laforin, but not malin, can interact physically with 
the catalytic subunit of AMPK and that purified AMPK phosphorylates GST::laforin in 
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vitro. Moreover, we demonstrate that the addition of a dominant negative form of the 
catalytic subunit of AMPK (DN-AMPK) prevents the function of the laforin-malin 
complex on the glycogenic activity of PTG, probably by interfering with the interaction 
between laforin and malin. As a result of this interference, malin is no longer able to 
access its substrates, laforin and PTG, thus the degradation of these two proteins is 
prevented. 
These data provide evidence for an additional function of AMPK in glycogen 
metabolism, where its activation is known to lead to an increase in the phosphorylation 
and inactivation of GS and also to an increase in glucose uptake [(53), (54), (55)]. 
However, in FTO2B hepatoma cells, the contribution of these two mechanisms to the 
overall regulation of glycogen accumulation seems to be fairly low since treatment of 
these cells with AICAR (an AMPK activator) did not promote glycogen accumulation 
and treatment of Ad-GFP-PTG-infected cells with AICAR did not change the amount of 
glycogen accumulated in comparison with untreated Ad-GFP-PTG-infected cells. These 
results suggest that in these cells, the regulation of the function of PTG is key to adjust 
glycogen accumulation. A diagram depicting our hypothesis with the potential roles of 
the laforin-malin complex, its relationship with other proteins in glycogen metabolism 
and the differences between the mechanism operating in neurons and FTO2B hepatoma 
cells is provided in Fig. 8. 
Recently, an alternative function of laforin on glycogen homeostasis has been 
described (27). In this case, laforin acts as a phosphatase of complex carbohydrates (i.e. 
amylopectin) and it has been proposed that this function might be necessary for the 
maintenance of normal cellular glycogen. 
In addition to PTG, malin and AMPK, laforin has been shown to interact with 
other proteins [(17), (16), (18), (19), (20)], suggesting that there are other regulatory 
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roles for the laforin-malin complex besides glycogen metabolism. This is an important 
issue because it is currently unknown whether Lafora bodies have a causative 
relationship with the epilepsy and neurodegeneration, or whether these LD features are 
independent consequences that result from the disturbance of a common physiological 
pathway. In this sense, it has been recently described that defects in protein degradation 
and clearance are likely to be the primary trigger in the pathophysiology of LD (56). 
Further elucidation of the mechanisms by which the formation of the laforin-malin 
complexes is regulated and of the mechanisms by which these complexes regulate PTG 
and glycogen synthesis in general, should lead to significant advances in the 
understanding of the pathogenesis of LD and hopefully, to the development of 
therapies. 
 
MATERIALS AND METHODS 
Recombinant plasmids 
pGBT9-laforin and pACT2-laforin plasmids have been described previously 
(20). Plasmids pEG202-laforin and pGEX6P1-laforin were obtained by subcloning a 
BamHI/SalI fragment from pGBT9-laforin into pEG202 (Clontech) and pGEX6P1 
(Amersham Biosciences), respectively. Malin was amplified from human genomic 
DNA by PCR and cloned into the prokaryote vector pGEX-A (Invitrogen). The final 
construct, pGST::malin, encoded a recombinant malin protein with GST fused at its N-
terminus. Malin cDNA was also cloned into pcDNA3-HA (Invitrogen) and the yeast 
vectors pEG202 and pACT2 (Clontech). Laforin and malin containing plasmids were 
also used as templates for the introduction of EPM2A and EPM2B missense and 
nonsense mutations by PCR, using the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene) and appropriate mutagenic oligonucleotides. All expression constructs 
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were fully sequenced to exclude the presence of undesired mutations resulting from 
PCR amplification. A pCINeo::laforin plasmid was used to express laforin in COS7 or 
HEK293 cells. A constitutively active form of the kinase domain of 2 catalytic subunit 
of AMPK (KDT172D) was constructed as in Scott et al. (41). The fragment was 
subcloned into plasmid pSK93 (57) to obtain plasmid pSK-KDT172D (58). Wild type 
laforin and C266S mutant cDNAs were also subcloned into plasmid pSK93 to obtain 
plasmids pSK-Laforin and pSK-Laforin C266S. Plasmids pACT2-AMPK2, pACT2-
AMPK2, pACT2-AMPK1 and pCMV-HA-AMPK2 are described in (58).  
 
Yeast two hybrid analyses  
Yeast CTY10.5d strain was co-transformed with pACT2-laforin and different 
pEG202-malin plasmids (wild type and mutants). -Galactosidase activity was assayed 
in permeabilized cells and expressed in Miller Units as in (59). For the yeast two-hybrid 
analyses using pGBT9-laforin (wild type and mutants) as bait, yeast strain AH109 
(Clontech) was co-transformed with pACT2-malin plasmid. Transformants were 
analyzed as in (20). 
 
Expression of recombinant proteins in E.coli 
E.coli transformants harboring different GST-fusions were grown in 500 ml of 
LB/ampicillin. Transformants were grown at 37ºC until the absorbance at 600 nm 
reached a value of around 0.3. IPTG (isopropyl--D-thiogalactoside) was then added to 
a concentration of 0.1 mM, and cultures were maintained overnight at 25 ºC. Cells were 
harvested and resuspended in 20 ml of sonication buffer 50 mM HEPES-NaOH pH 7.0, 
150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 2 mM DTT, 2 mM PMSF and 
complete protease inhibitor cocktail (Roche)]. Cells were disrupted by sonication and 
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the fusion proteins purified by passing the extracts through 1 ml bed volume of 
glutathione-sepharose columns (Amersham Biosciences). GST-fusion proteins were 
eluted from the column with 25 mM glutathione. Samples were stored at -80ºC. 
 
Co-immunoprecipitation and GST pull-down analyses 
Immunoprecipitations were performed using transfected human embryonic 
kidney HEK293 cells. To identify laforin-AMPK2 complexes, subconfluent cultures 
of HEK293 cells growing in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with 10% inactivated fetal bovine serum (FBS, GIBCO) plus 
100 units/ml penicillin, 100 g/ml streptomycin and 2 mM glutamine, were co-
transfected with 3 g of pCINeo-laforin and 3 g of pCMV-HA-AMPK2, using the 
calcium phosphate protocol. Transfected cells were scraped in lysis buffer [50 mM 
TrisHCl pH 7.5; 10 mM NaCl, 50 mM EDTA; 15% glycerol, 1% nonidet P-40 (NP-40), 
complete protease inhibitor cocktail (Roche), 1 mM PMSF, 50 mM NaF and 5 mM 
Na2P2O7]. Cells were lysed by successive rounds of freeze and thawing. Cell lysates 
were then centrifuged at 13,000xg for 15 min at 4ºC. Laforin-AMPK2 complexes were 
immunoprecipitated from the supernatants (500 g of total protein) with anti-HA 
monoclonal antibody. Western blots of the immunoprecipitates were probed with a 
monoclonal anti-laforin antibody and a sheep anti-mouse IgG conjugated to HRP. The 
HRP signal was detected by using the ECL plus western blotting detection system 
(Amersham Biosciences). 
 
Immunoblotting 
Sixty g of total protein from the soluble fraction of cell lysates prepared as 
above were analyzed by SDS-PAGE and western blotting using appropriate antibodies: 
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rabbit polyclonal anti-GFP (Molecular Probes), rabbit polyclonal anti-GS (60), rabbit 
polyclonal anti-phospho Ser461 GS (Cell signalling), mouse monoclonal anti-laforin 
(20), rabbit polyclonal anti-LexA (Invitrogen), mouse monoclonal anti-HA (Sigma), 
rabbit polyclonal anti-actin (Sigma) and rabbit polyclonal anti-AMPK (Cell Signaling). 
 
In vitro ubiquitination assay 
Ubiquitination assays were carried out by mixing purified GST- recombinant 
proteins [full length malin; malin-C26S and malin-D146N], mammalian E1 (5 ng/l; 
Biomol), one type of mammalian E2 [UbcH7 or UbcH5a, or inactive [C85A] UbcH5a 
(25 ng/l, Affinity)] and ubiquitin (100 ng/l; Sigma), in ubiquitination buffer (250 mM 
Tris-HCl pH 7.4, 12.5 mM MgCl2, 2.5 mM DTT and 10 mM ATP). Samples were 
incubated at 25ºC for 1.5 hr and reactions were stopped by boiling the mixtures in SDS-
PAGE sample buffer for 10 min. Proteins were separated by SDS-PAGE and visualized 
by immunoblotting using anti-GST (Santa Cruz Biotechnology) and anti-ubiquitin 
(FK2, Biomol) monoclonal antibodies. 
 
Analysis of in vivo ubiquitination of PTG 
To study the in vivo ubiquitination of PTG, HEK293 cells were transfected with 
pCMV-myc-R5 and combinations of pCMV-Ubiqx6His (encoding a modified ubiquitin, 
tagged with 6 His residues; a gift from Dr. M. Rodriguez, Proteomics Unit, CIC-
BioGUNE, Vizcaya), pcDNA3-HA-malin or pCIneo::laforin plasmids, using the 
Fugene HD reagent (Roche) according to the manufacturer´s instructions. After thirty-
six hours of transfection, cells were lysed in buffer A (6 M guanidinium-HCl, 0.1 M 
sodium phosphate, 0.1 M  Tris-HCl, pH 8.0). Four mg of protein of a clarified extract 
(12,000 g, 15 min) was incubated with a 100 l of a TALON column (Clontech) in the 
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presence of 10 mM imidazole, for 3 hours at room temperature on a rocking platform, to 
purify His-tagged proteins. The column was then successively washed with 2 ml each of 
buffer B (buffer A plus 10 mM imidazole), buffer C (buffer B, but with 8 M urea 
instead of 6 M guanidinium-HCl) and four more times with buffer C adjusted to pH 6.0. 
Bound proteins were eluted with 50 l 2x Laemmli’s sample buffer and analyzed by 
Western-blotting with an anti-myc monoclonal antibody (Sigma). 
 
AMPK in vitro phosphorylation assay 
50 ng of purified GST-fusion proteins were phosphorylated with 50 mU of 
AMPK (Upstate), in a final volume of 20 l of a buffer containing 20 mM HEPES-
NaOH pH 7.0, 1 mM dithiothreitol, 10 mM MgCl2, 300 M AMP and 100 M of a 
mixture of -32P-ATP (3,000 Ci/mmol) and cold ATP, following the manufacturer’s 
instructions (Upstate). The reaction was incubated at 30ºC for 1 hr and stopped by 
boiling the mixtures in sample buffer. Samples were analyzed by SDS-PAGE and 
autoradiography. 250 ng of GST-fusion proteins were analyzed by SDS-PAGE and 
stained with Coomassie blue. 
 
Adenovirus infection 
Rat hepatoma FTO2B cells were cultured in complete Dulbecco’s Modified 
Eagle’s medium (DMEM, Invitrogen) supplemented with 10% inactivated fetal bovine 
serum (FBS, GIBCO), 100 units/ml penicillin, 100 g/ml streptomycin and 2 mM 
glutamine. 106 cells were plated onto 60 mm-diameter culture dishes the day before 
infection. Infection with the corresponding adenovirus was carried out in 1 ml of 
complete DMEM containing 0.5% FBS. The following adenovirus were used in this 
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work: Ad-GFP (1011 pfu/ml), Ad-GFP-PTG (2x1011 pfu/ml), Ad-laforin (2x1012 pfu/ml) 
and Ad-malin (4x1012 pfu/ml) (31), and Ad-DN-AMPK (1011 pfu/ml; kindly supplied 
by Dr. Pascal Ferré, INSERM Unit 671, Universite Paris 6, Centre de Recherches 
Biomedicales des Cordeliers, Paris, France). Two hours after infection, adenovirus-
containing medium was replaced with fresh complete DMEM containing 0.5% FBS. 24 
hours after infection, cells were washed with PBS and frozen in liquid N2 until analysis.  
Primary fibroblasts from the skin of two LD patients, carrying the Y86X and 
R241X laforin mutations, were cultured using standard procedures and were routinely 
transformed using a plasmid (T22) containing the SV40 T antigen (kindly supplied by 
Dr. M. Ugarte, Universidad Autónoma de Madrid, Spain). GM03349 fibroblasts from 
human skin (Coriell Cell Repositories, USA.) were used as healthy controls. Fibroblasts 
were cultured in complete DMEM supplemented with 15% inactivated FBS. 150,000 
cells were plated onto 60 mm-diameter culture dishes for three days. Fibroblasts were 
then infected with the corresponding adenoviruses as above. 
 
Glycogen and GS activity determination 
To measure glycogen content, cell monolayers were scraped into 30% KOH and 
the extract was then heated at 100ºC for 15 min. Glycogen was then measured as 
described previously (61). The amount of glycogen is expressed as the amount of 
released glucose per mg of total protein. GS activity was measured in cell homogenates 
in the absence or presence of 6.6 mM Glu-6P, as described previously (62). The –Glu-
6P/+Glu6P activity ratio is a non-linear measurement of the activation state of the 
enzyme. Values below 0.1 indicate an essentially fully inactive enzyme, whereas values 
above 0.7 are equivalent to full activation (63). 
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Statistical data analysis. 
Data are expressed as means ± standard deviation (SD). Statistical significance 
of differences between the groups was evaluated by a paired Student’s t test with two-
tailed distribution. The significance has been considered at * p<0.05, ** p<0.01, and 
*** p<0.001, as indicated in each case. 
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LEGENDS TO FIGURES 
Fig. 1. Laforin tethers the interaction between PTG and malin. Yeast CTY10-5d 
strain was transformed with plasmids pEG202-PTG (LexA.PTG), pACT2-malin (GAD-
malin) or pACT2 (GAD, empty plasmid) and plasmids pSK93 (empty), pSK-laforin or 
pSK-laforin C266S. Transformants were grown until exponential phase (A600 0.5) in 
selective SC medium containing 4% glucose. Protein interaction was estimated using 
the yeast two-hybrid system, by measuring the -galactosidase activity. Values 
correspond to means from 4-6 different transformants (bars indicate standard deviation), 
** p<0.01. 
 
Figure 2. Laforin-malin complex counteracts the glycogenic effect of PTG. A) Rat 
hepatoma FTO2B cells were infected with increasing amounts of Ad-GFP-PTG 
adenovirus or with 30 l of Ad-GFP adenovirus. Twenty-four hours after the infection, 
the amount of glycogen was determined as described in Materials and Methods. Bars 
indicate standard deviation of three independent experiments (** p<0.01; *** p<0.001). 
B) FTO2B cells were infected with 300 l of Ad-GFP-PTG and increasing amounts of 
Ad-laforin and Ad-malin adenovirus. Twenty-four hours after the infection, the amount 
of glycogen was determined as described in Materials and Methods. Bars indicate 
standard deviation of at least three independent experiments (*** p<0.001). C) Cell 
extracts (60 g) from FTO2B cells treated as in section B) were obtained and analyzed 
by western blotting using anti-GFP, anti-GS, anti-phospho Ser461 GS, anti-actin, anti-
laforin or anti-HA antibodies (Ad-malin adenovirus produces an N-terminal HA-tagged 
malin). 
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Fig. 3. PTG is ubiquitinated in vivo. HEK293 cells were transfected with pCMV-myc-
PTG and with the indicated combinations of pCMV-Ubiqx6His, pcDNA3-HA-malin 
and pCIneo::laforin plasmids. Thirty-six hours after transfection, cells were broken in 
lysis buffer containing guanidinium-HCl (see Materials and Methods) and 4 mg of 
protein of clarified extracts were loaded on a TALON column. The column was 
extensively washed and finally eluted with 2x Laemmli sample buffer. 100 g of 
clarified extracts and the eluted fraction from the TALON column were analyzed by 
immunoblotting using anti-myc antibodies. The unmodified myc-PTG protein is 
retained unspecifically in the TALON column (asterisk). 
 
Figure 4. AMPK regulates the interaction between laforin and malin. A) The 
laforin-malin interaction is enhanced by low glucose. Yeast CTY10-5d strain was 
transformed with plasmids pEG202-Laforin (LexA-laforin) and pACT2-malin (GAD-
malin) or the empty plasmid pACT2 (GAD). Transformants were grown until 
exponential phase (A600 0.5) in selective SC medium containing 4% glucose, and then 
washed with water and transferred to a 0.05% glucose medium for 3 hours. Protein 
interaction was estimated using the yeast two-hybrid system, by measuring the -
galactosidase activity. Values correspond to means from 4-6 different transformants 
(bars indicate standard deviation), *** p<0.001. B) Yeast FY250 wild type, gac1 and 
snf1 mutant strains containing the reporter plasmid pSH18-18 (6lexAop-lacZ) were 
transformed with plasmids pEG202-laforin and pACT2-malin. Transformants were 
grown until exponential phase (A600 0.5) in selective SC medium containing 4% 
glucose, and then washed with water and transferred to a 0.05% glucose medium for 3 
hours. Protein interaction was estimated using the yeast two-hybrid system, by 
measuring the -galactosidase activity. Values represent means of 4-6 different 
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transformants (bars indicate standard deviation), *** p<0.001. C) Yeast CTY10-5d 
strain containing plasmids pEG202-laforin and pACT2-malin was transformed with 
plasmids pSK93 (empty) or pSK-KDT172D, expressing a constitutively active form of 
AMPK2 subunit. Transformants were grown until exponential phase (A600 0.5) in 
selective SC medium containing 4% glucose. Protein interaction was estimated using 
the yeast two-hybrid system, by measuring the -galactosidase activity. Values 
represent means of 4-6 different transformants (bars indicate standard deviation), *** 
p<0.001. 
 
Figure 5. AMPK interacts with and phosphorylates laforin. A) Yeast CTY10-5d 
strain was transformed with plasmids pACT2-AMPK2, pACT2-AMPK2, pACT2-
AMPK1 or pACT2 (empty; GAD) and pEG202-laforin (LexA-laforin) or pEG202-
malin (LexA-malin). Cells were grown until exponential phase (A600 0.5) in selective 
SC medium containing 4% glucose. Protein interaction was estimated using the yeast 
two-hybrid system, by measuring the -galactosidase activity. Values represent means 
of 4-6 different transformants (bars indicate standard deviation), *** p<0.001. B) 
Laforin co-immunoprecipitates with AMPK2. HEK293 cells were transfected with 
pCINeo::laforin and pCMV-HA-AMPK2 (HA-2). Complexes between AMPK2 
and laforin were immunoprecipitated from lysates using an anti-HA monoclonal 
antibody. Western blots of immunoprecipitates were probed with an anti-laforin 
monoclonal antibody. Cell extracts and IP in the absence of antibody () are included 
as controls.  C) GST::Laforin (300 ng) and GST (100 ng), produced in bacteria and 
affinity purified using GSH-agarose, were phosphorylated in vitro using 50 mUnits of 
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AMPK (Upstate) and [-32P]ATP, following the manufacturer’s instructions. Samples 
were analyzed by SDS-PAGE and autoradiography. Size standards are indicated in kDa. 
 
Figure 6. DN-AMPK prevents the effect of the laforin-malin complex on PTG. A) 
Rat hepatoma FTO2B cells were infected with Ad-GFP-PTG (300 l) or Ad-GFP (30 
l) and Ad-DN-AMPK (300 l). Twenty-four hours after the infection, an aliquot of 
Ad-GFP-PTG infected cells was treated with AICAR (0.5 mM, 6h) and the amount of 
glycogen in all the samples was determined as described in Materials and Methods. Bars 
indicate standard deviation of five independent experiments; *** p<0.001). B) FTO2B 
cells were infected with Ad-GFP-PTG (300 l) and also with either Ad-GFP (30 l), a 
combination of Ad-laforin and Ad-malin (100 l each) or a combination of Ad-laforin, 
Ad-malin (100 l each) and Ad-DN-AMPK (300 l). Twenty-four hours after the 
infection, the amount of glycogen was determined as described in Materials and 
Methods. Bars indicate standard deviation of five independent experiments; *** 
p<0.001. C) Cell extracts (60 g) from FTO2B cells treated as in section B) were 
obtained and analyzed by western blotting using anti-GFP, anti-laforin, anti-HA (Ad-
malin adenovirus produces an N-terminal HA-tagged malin), anti-AMPK anti-GS or 
anti-actin antibodies. 
 
Figure 7: The effect of DN-AMPK on the glycogenic activity of PTG requires the 
presence of laforin. A) Primary fibroblasts from a healthy control and from LD-
patients with the laforin mutations Y86X and R241X were infected with low dose (30 
l) of Ad-GFP or Ad-GFP-PTG adenovirus in combination with or without Ad-DN-
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AMPK (300 l). Twenty-four hours after the infection, the amount of glycogen was 
determined as described in Materials and Methods. The increase in the glycogen content 
with respect to the treatment with Ad-GFP is plotted. Bars indicate standard deviation of 
three independent experiments. Only in healthy control fibroblasts, a statistically 
significant difference in the levels of glycogen of cells treated with Ad-GFP-PTG in 
combination or not with Ad-DN-AMPK was observed (* p<0.05, ** p<0.01, *** 
p<0.001). B) Crude extracts (60 g) from cells treated as in section A) were obtained 
and analyzed by western blotting using anti-GFP and anti-AMPK antibodies. The 
position of an anti-GFP cross-reacting band is indicated with an asterisk. 
 
Figure 8. Proposed role for the laforin-malin complex, PTG and AMPK in 
glycogen biosynthesis. See text for details. PP1c: catalytic subunit of type 1 protein 
phosphatase; LGS: liver glycogen synthase isoform; MGS: muscle glycogen synthase 
isoform; Ph: glycogen phosphorylase. 
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ABBREVIATIONS 
AMPK, AMP-activated protein kinase; GS, glycogen synthase; LD, Lafora progressive 
myoclonus epilepsy; Ph, glycogen phosphorylase; PhK, glycogen phosphorylase kinase; 
PP1, protein phosphatase type1; PTG, protein targeting to glycogen;  
 
